...
首页> 外文期刊>Cell death discovery. >Increased Krüppel-like factor 12 impairs embryo attachment via downregulation of leukemia inhibitory factor in women with recurrent implantation failure
【24h】

Increased Krüppel-like factor 12 impairs embryo attachment via downregulation of leukemia inhibitory factor in women with recurrent implantation failure

机译:反复植入失败的女性中,Krüppel样因子12的增加通过白血病抑制因子的下调而损害胚胎附着

获取原文
           

摘要

Recurrent implantation failure (RIF) caused by various etiological factors remains a challenge for fertility clinicians using assisted reproductive technology (ART) worldwide. Dysregulation of leukemia inhibitory factor (LIF) in the endometria of women with RIF is involved in impaired endometrial receptivity and embryo adhesion. However, the mechanism through which LIF expression is regulated in women with RIF is still poorly understood. Our previous study noted that the abnormally increased endometrial Krüppel-like factor 12 (KLF12) in RIF women led to impaired decidualization and embryo implantation. Here, we further found that KLF12 inhibited embryo adhesion in vivo and in vitro by repressing LIF expression. Mechanistically, KLF12 bound to conserved sites (CAGTGGG, ?6771 to ?6765 and ?7115 to ?7109) within the LIF promoter region and repressed LIF transcription directly. Exogenous LIF significantly reversed the KLF12-mediated repression of BeWo spheroid adhesion. KLF12 expression was reduced significantly in Ishikawa cells treated with progestogen, which was due to the activation of Akt signaling. These findings may provide novel potential therapeutic regimens for patients with RIF and disrupted endometrial receptivity.
机译:由各种病因引起的复发性植入失败(RIF)仍然是全球范围内使用辅助生殖技术(ART)的生育临床医生的一项挑战。患有RIF的女性子宫内膜中的白血病抑制因子(LIF)调节异常与子宫内膜容受性和胚胎黏附受损有关。但是,对RIF妇女中LIF表达调控的机制仍知之甚少。我们之前的研究指出,RIF妇女子宫内膜Krüppel样因子12(KLF12)异常增加导致蜕膜蜕膜和胚胎植入受损。在这里,我们进一步发现KLF12通过抑制LIF表达在体内和体外抑制胚胎粘附。从机制上讲,KLF12结合至LIF启动子区域内的保守位点(CAGTGGG,?6771至?6765和?7115至?7109)并直接抑制LIF转录。外源LIF显着逆转了KLF12介导的BeWo球体粘附的抑制。在孕激素处理的石川细胞中,KLF12表达显着降低,这是由于Akt信号转导的激活所致。这些发现可能为RIF和子宫内膜容受性受损的患者提供新颖的潜在治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号